IDO1-IN-19

Overview

IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC 50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC 50 s of 12 μM ( IKr ), 40 μM ( INa ), 8.3 μM ( ICa ), respectively. IDO1-IN-19 has the potential to study cancer diseases.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Hypertension | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Indoleamine 2,3-Dioxygenase (IDO) | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > Sodium Channel | Products > Signaling Pathways > Potassium Channel | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-144652
• CAS No.: 2328099-11-0
• Molecular Formula: C25H22F4N2O3
• Molecular Weight: 474.45
• Purity: 98.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution
• Availability: In-stock

Source

Original product source